Policy Feedback
Step 1 of 4: Enter your comments on individual clauses
In step 1 provide your comments on specific content. Select (comment icon ) to open a comment box to type your feedback then click "save comment" to close the comment box. In step 2 you will provide general comments.
Important tips to avoid losing your comments or corrupting your entries:
- AVOID jump between web pages or applications while commenting – open a new browser window if you need to to switch
- ONLY log comments for one policy at a time.
- DON'T leave your submission half way through. If you need to take a break, submit your current set of comments. You can go back in and start a new comments , just jump to where you left off.
(1) This Guideline aims to provide information about Q-Fever and how to reduce the risk of (2) These Guidelines apply to all relevant (3) Workers and (4) Q-Fever is a zoonotic infection transmitted by the bacterial microorganism Coxiella burnetii, usually via dust and aerosols from infected animals. It is a relatively common but preventable condition which, while rarely fatal, can cause a severe acute illness with complications such as hepatitis and pneumonia. It can also cause damage to heart valves and precipitate chronic fatigue and long-term disability. (5) The organism can infect both wild and domestic animals and their ticks. Companion animals such as cats and dogs can also become infected. (6) Persons working with animals such as cattle, sheep, goats and feral animals have the greatest risk of transmission and those most at risk include workers from the meat and livestock industry and sheep shearers. Persons working or living in areas frequented by these animals but not actually working with the animals are at some risk also. Persons dealing with animal products in the research setting can also be at risk. (7) Q-Fever is primarily an occupational disease of workers from the livestock and meat industry. Over 90% of cases of acute Q-Fever occur in new entrants to the workforce or those who have been in the workforce 5 years or less. Q-Fever affects mainly men between 20 and 50. Women entering high-risk occupations should be vaccinated before considering a pregnancy to avoid the significant risk to the foetus in the event of Q-Fever infection occurring during pregnancy. (8) Coxiella burnetii infects both wild and domestic animals and their ticks, sometimes without any apparent signs of infection. Cattle, sheep and goats are the main reservoirs of human infection, although bandicoots, kangaroos, wallabies, birds, rodents, lagomorphs (hares, rabbits, and pikas), cats and dogs also can be infected. Infected animals shed Coxiella burnetii in their urine, faeces, milk and in particularly high numbers in birth products. (9) Coxiella burnetii is a highly infectious bacterium that can survive in harsh environmental conditions. For example, it has survived for 7 to 9 months on wool at 15 to 20oC, for more than 1 month on fresh meat in cold storage and for more than 40 months in skim milk at 4 to 6oC. It is transmitted to humans via inhalation, ingestion, inoculation or via direct contact with infected aerosols or dust. (10) The predominant mode of infection of humans is via the respiratory tract after inhalation of airborne dust or droplets containing the coxiella. Large numbers of Coxiella burnetii are released in the blood, urine, faeces, milk, birth fluids and placenta of infected animals. Infected aerosols from these products may be released into the environment and consequently infect humans via the respiratory tract. Infected aerosols are released during the slaughter of infected animals or for example during incorrect handling of the above animal products in the research environment. (11) Coxiella burnetii can survive in dust formed from contaminated birth fluids, blood, faeces or urine. When infected fluids dry out, the bacterium can survive in the dust for many years. Infected dust may settle on the ground, on wool, hides, clothing, straw etc and be disturbed by movement or wind. Contaminated dust can be carried outside the working environment on work clothing, hair, straw, and other formites or on working dogs. (12) Consumption of unpasteurised infected milk or milk products such as unripened cheese can lead to infection but is considered to have a lower risk of transmission compared to airborne exposure. (13) Infection can occur through subcutaneous inoculation such as being bitten by infected ticks or via a needle stick injury when working with laboratory animals. Human to human transmission is rare but has been known to occur via blood transfusion from blood collected in the late incubation period of primary infection. (14) Infection can occur through direct contact with infected material or dust via the conjunctiva and other mucous membranes. (15) Symptoms range greatly, with some infected people experiencing no symptoms whilst some feel mildly unwell for a few days. Most people however experience severe flu-like symptoms with fever, sweating, nausea, vomiting and diarrhoea for up to 10 days. Some people may experience post Q-Fever Fatigue Syndrome resulting in a prolonged form of the illness with symptoms of tiredness, muscle weakness, headaches and depression continuing for years after the initial infection. Some people with heart problems can experience a severe illness due to complications caused by the heart valves becoming infected. (16) A risk assessment should be undertaken in workplaces where agricultural or feral animals are handled or are housed in close proximity to work areas to establish: (17) The following factors should be considered as part of a risk assessment:: (18) The most appropriate risk mitigation options are subject to consultative risk assessment and may include: (19) Completion and periodic review of risk assessment to mitigate the risk of Q-Fever may identify persons that would benefit from pre-screening and vaccination. (20) Consideration should be given but not limited to (21) UNE is able to offer these services according to this Guideline to relevant persons. (22) Pre-screening and vaccination for Identified Persons is offered by UNE via the UNE Life Healthcare Centre. (23) 'Identified Persons' (or groups) are those that are specified in a risk assessment process. Individual names of those eligible to access the UNE program for Q-Fever pre-screening and vaccination will be forwarded by the relevant (24) Identified Persons will be informed by the relevant UNE (25) Relevant UNE (26) Q-Fever clinic date and times are to be promoted by the relevant School via appropriate channels that access both (27) It is the responsibility of (28) Failure to attend a confirmed appointment for pre-screening and/or vaccination may result in the fee being charged to the individual at the discretion of the UNE Life Healthcare Centre and relevant UNE Head of School. (29) For (30) Screening prior to vaccination is undertaken to exclude persons who are already sensitised to Q-Fever antigens and who may therefore experience a severe hypersensitivity reaction if vaccinated. (31) Pre-vaccination screening incorporates taking a detailed history to exclude the likelihood of the person previously having had Q-Fever infection or being previously vaccinated with the Q-Fever vaccine. (32) Further screening tests may be undertaken such as a skin-prick test during the initial consultation and a blood test at a pathology centre to detect immunological evidence of previous Q-Fever exposure. (33) A follow up Q-Fever Clinic appointment must be scheduled for the full program to be complete. (34) Results of the pre-screening test will be assessed and if deemed necessary, the Q-Fever vaccine will be administered during the consultation. (35) The Australian Q-Fever Register is a database that stores information about the immune status of people who have undertaken Q-Fever screening and who consent to being listed on the register. It allows those who may have forgotten or lost their Q-Fever screening or immunisation details to quickly recover this information. Those listed on the register can be safely employed in a new job where there is a risk of contracting Q-Fever without having to re-test. Being on the register can also help avoid the risk of adverse reactions occurring when a person who is already immune to Q-Fever is inadvertently re-vaccinated. (36) Information on the Q-Fever register can only be entered with the consent of the immunised person. (37) The Procedure Administrator, the Director People and Culture, pursuant to the University's Work Health and Safety (WHS) Rule, makes these Guidelines. (38) (39) These Guidelines operate as and from the (40) Previous Guidelines relating to Q-Fever Risk Mitigation are replaced and have no further operation from the (41) Antigens are substances that can stimulate the immune system to produce antibodies. (42) Bacterium means a single cell micro-organism, some of which can cause disease. (43) A Worker, as defined by the WHS Act, is a person that carries out work in any capacity for a person conducting a business or undertaking, including work as: (44) Zoonotic, pertaining to zoonosis, a disease that normally exists in animals but can be transmitted from animals to humans.WHS G004 Q-Fever Risk Mitigation Guideline
Section 1 - Overview
Section 2 - Scope
Section 3 - Guideline
About Q-Fever
Modes of Transmission
Inhalation (air borne)
Ingestion
Inoculation
Direct Contact
Symptoms of Q-Fever
Risk Assessment
Risk Mitigation Options
Access to Pre-Screening and Vaccination
Pre Screening Process
Vaccination Process
Q-Fever Register
Authority and Compliance
Section 4 - Definitions